1
|
Tang J, Liu H, Wang Q, Gu X, Wang J, Li W, Luo Y, Li Y, Deng L, Luo Y, Du X, Tan D, Fu X, Chen X. Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China. Front Immunol 2023; 14:1191479. [PMID: 37388736 PMCID: PMC10303911 DOI: 10.3389/fimmu.2023.1191479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 06/02/2023] [Indexed: 07/01/2023] Open
Abstract
Background Demographic information has been shown to help predict high antibody titers of COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the Chinese population and little evidence on whole-blood donors. Therefore, we aimed to investigate these associations among Chinese blood donors after SARS-CoV-2 infection. Methods In this cross-sectional study, 5,064 qualified blood donors with confirmed or suspected SARS-CoV-2 infection completed a self-reported questionnaire and underwent tests of SARS-CoV-2 Immunoglobulin G (IgG) antibody and ABO blood type. Logistic regression models were used to calculate odds ratios (ORs) for high SARS-CoV-2 IgG titers according to each factor. Results Totally, 1,799 participants (with SARS-CoV-2 IgG titers≥1:160) had high-titer CCPs. Multivariable analysis showed that a 10-year increment in age and earlier donation were associated with higher odds of high-titer CCP, while medical personnel was associated with lower odds. The ORs (95% CIs) of high-titer CCP were 1.17 (1.10-1.23, p< 0.001) and 1.41 (1.25-1.58, p< 0.001) for each 10-year increment in age and earlier donation, respectively. The OR of high-titer CCP was 0.75 (0.60-0.95, p = 0.02) for medical personnel. Female early donors were associated with increased odds of high-titer CCP, but this association was insignificant for later donors. Donating after 8 weeks from the onset was associated with decreased odds of having high-titer CCP compared to donating within 8 weeks from the onset, and the HR was 0.38 (95% CI: 0.22-0.64, p <0.001). There was no significant association between ABO blood type or race and the odds of high-titer CCP. Discussion Older age, earlier donation, female early donors, and non-medical-related occupations are promising predictors of high-titer CCP in Chinese blood donors. Our findings highlight the importance of CCP screening at the early stage of the pandemic.
Collapse
Affiliation(s)
- Jingyun Tang
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Humin Liu
- Department of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Qing Wang
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xiaobo Gu
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Jia Wang
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Wenjun Li
- Department of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Yinglan Luo
- Department of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Yan Li
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Lan Deng
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Yue Luo
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xinman Du
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Donglin Tan
- Department of Blood Processing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xuemei Fu
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xue Chen
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| |
Collapse
|
2
|
Domènech-Montoliu S, Puig-Barberà J, Guerra-Murcia O, Pac-Sa MR, Orrico-Sanchéz A, Gómez-Lanas L, Sala-Trull D, Domènech-Leon C, Del Rio-González A, Sánchez-Urbano M, Satorres-Martinez P, Latorre-Poveda M, Ferrando-Rubert S, Aparisi-Esteve L, Badenes-Marques G, Blasco-Gari R, Casanova-Suarez J, Fontal-Carcel M, Gil-Fortuño M, Hernández-Pérez N, Jovani-Sales D, López-Diago L, Notari-Rodríguez C, Pérez-Olaso O, Romeu-Garcia MA, Ruíz-Puig R, Arnedo-Pena A. ABO Blood Groups and Incidence of COVID-19 in the Mass Gathering Events in Borriana (Spain), March 2020: A Retrospective Cohort Study. EPIDEMIOLOGIA 2023; 4:63-73. [PMID: 36810454 PMCID: PMC9944070 DOI: 10.3390/epidemiologia4010007] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 01/19/2023] [Accepted: 01/24/2023] [Indexed: 02/01/2023] Open
Abstract
Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6-10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83-1.04), for A-group 1.06 (95% CI 0.94-1.18), for B-group 1.04 (95%CI 0.88-1.24), and for AB-group 1.11 (95% CI 0.81-1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.
Collapse
Affiliation(s)
| | - Joan Puig-Barberà
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
| | - Olga Guerra-Murcia
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
| | | | - Alejandro Orrico-Sanchéz
- Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
| | - Lorna Gómez-Lanas
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Diego Sala-Trull
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | | | | | | | | | | | | | | | - Roser Blasco-Gari
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | | | - María Gil-Fortuño
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - David Jovani-Sales
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Laura López-Diago
- Clinical Analysis Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - Oscar Pérez-Olaso
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain
| | | | - Raquel Ruíz-Puig
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain
| | - Alberto Arnedo-Pena
- Public Health Center, 12003 Castelló de la Plana, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Department of Health Science, Public University Navarra, 31006 Pamplona, Spain
- Correspondence:
| |
Collapse
|
3
|
Díaz-Salazar S, Navas R, Sainz-Maza L, Fierro P, Maamar M, Artime A, Basterrechea H, Petitta B, Pini S, Olmos JM, Ramos C, Pariente E, Hernández JL. Blood group O is associated with post-COVID-19 syndrome in outpatients with a low comorbidity index. Infect Dis (Lond) 2022; 54:897-908. [DOI: 10.1080/23744235.2022.2115548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- Sara Díaz-Salazar
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Raquel Navas
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
| | - Laura Sainz-Maza
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
| | - Patricia Fierro
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Meryam Maamar
- Emergency Service. Osakidetza. Servicio Vasco de Salud, Bilbao, Spain
| | - Arancha Artime
- El Llano - Primary Care Center. SESPA- Servicio Asturiano de Salud, Gijón, Spain
| | - Héctor Basterrechea
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Benedetta Petitta
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Stefanie Pini
- Hospital at Home Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - José Manuel Olmos
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
- Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla. Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - Carmen Ramos
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
| | - Emilio Pariente
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
| | - José Luis Hernández
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
- Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla. Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| |
Collapse
|